SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 5, 2003
Array BioPharma Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-31979 |
|
84-1460811 |
|
(State or Other |
|
(Commission |
|
(IRS Employer |
|
|
|
|
|
|
|
3200 Walnut Street, Boulder, Colorado |
|
80301 |
||
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s telephone number, including area code: (303) 381-6600
(Former Name or Former Address, if Changed Since Last Report)
ITEM 9. REGULATION FD DISCLOSURE
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On May 5, 2003, the registrant issued a press release reporting financial results for the third quarter of fiscal year 2003, the full text of which is attached hereto as Exhibit 99.1. This information is also being furnished pursuant to Item 12 of Form 8-K.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ARRAY BIOPHARMA INC. |
|
|
|
|
|
|
|
|
|
|
Date: May 5, 2003 |
By: |
/s/ Robert E. Conway |
|
|
|
Robert E. Conway |
|
|
|
Chief Executive Officer |
3
|
Exhibit No. |
|
|
|
|
|
|
|
99.1 |
|
Press release dated May 5, 2003 entitled “Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2003” |
4